CAS NO: | 133240-06-9 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Storage | Store at -20°C |
M.Wt | 175.2 |
Cas No. | 133240-06-9 |
Formula | C10H13N3 |
Solubility | insoluble in H2O; ≥45.7 mg/mL in EtOH; ≥5.3 mg/mL in DMSO |
Chemical Name | 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine |
Canonical SMILES | CC1=CC(C)=C2C(N1)=NC(CC)=N2 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine is a nonpeptidic angiotensin II receptor antagonist.
Angiotensin II is the critical pressor substance of the renin-angiotensin system (RAS). The angiotensin II system, a proteolytic cascade regulating hemodynamics and water and electrolyte balance, is able to contribute to hypertensive states in human. The effects of the octapeptide angiotensin I1 includs cardiac stimulation, vasoconstriction, stimulation of aldosterone synthesis and release, as well as renal reabsorption of sodium.
In vitro: In a previous study, 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was synthezed by reduction of 2-amino-3-nitropyridine derivatives to the corresponding diaminopyridine which was then condensed with an appropriate carboxylic acid in polyphosphoric acid. In vitro activity study showed that 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was a nonpeptidic angiotensin II receptor antagonist whose imidazo[4,5-b]pyridine scaffold had been used to examine plenty of positional substitutions in the development of orally active, long duration antihypertensive agents [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Mantlo, N. B.,Chakravarty, P.K.,Ondeyka, D.L., et al. Potent, orally active Imadazo[4,5-b]pyridine-based angiotensin II receptor antagonists. Journal of Medicinal Chemistry 34(9), 2919-2922 (1991).